




#1819  
#5819

PATENT  
ATTORNEY DOCKET NO. 04585/00200R

Certificate of Mailing	
Date of Deposit: <u>May 28, 1997</u>	
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as <b>first class mail</b> with sufficient postage on the date indicated above and is addressed to Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.	
<u>Matthew G. Doherty</u>	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew Goodearl et al.	Art Unit	:
Serial No.	: 08/734,592	Examiner	:
Filed	: October 22, 1996		
Title	: GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE		

RECEIVED  
JUN 19 1997  
GROUP 1800

Assistant Commissioner for Patents  
Washington, DC 20231

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 CFR § 3.73(b) Ludwig Institute for Cancer Research, a New York corporation, and Cambridge NeuroScience, a Delaware corporation, certify that together they are the assignees of 100% of the right, title and interest in the patent application.

The assignment from inventors Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, and Ian Hiles to Ludwig Institute for Cancer Research was recorded in the Patent and Trademark Office at Reel 6556, Frame 0263 on May 26, 1993. The assignment from inventors Mark Marchioni and Mario Su Chen to Cambridge

NeuroScience was recorded in the Patent and Trademark Office act Reel 6556, Frame 0262 on May 26, 1993.

The undersigned have reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigneds' knowledge and belief, title is in the assignees identified above.

The undersigned, whose titles are supplied below, are empowered to act on behalf of the assignees.

The undersigned, acting on behalf of the assignees, hereby revoke all powers of attorney previously granted in the application and appoint:

Kristina Bieker-Brady, Ph.D.  
Paul T. Clark  
Karen Elbing, Ph.D.  
Evelyn Shen  
Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110-2214

with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.


All correspondence regarding the application should be sent to Kristina Bieker-Brady, Ph.D. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like


so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: 5-23-97

  
\_\_\_\_\_  
Gregory B. Butler, Ph.D.  
Senior Director, Legal Affairs  
and Chief Patent Counsel  
Cambridge NeuroScience

Date: May 21, 1997

  
\_\_\_\_\_  
Edward A. McDermott, Jr.  
President  
Ludwig Institute for Cancer Research